2024

Ikaros sets the threshold for negative B-cell selection by regulation of the signaling strength of the AKT pathway
Ehm P, Horn S, Hoffer K, Kriegs M, Horn M, Giehler S, Nalaskowski M, Rehbach C, Horstmann M, Jücker M
CELL COMMUN SIGNAL. 2024;22(1):360.

K-Ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3
Geißert R, Lammert A, Wirth S, Hönig R, Lohfink D, Unger M, Pek D, Schlüter K, Scheftschik T, Smit D, Jücker M, Menke A, Giehl K
CELL COMMUN SIGNAL. 2024;22(1):85.

The Functional Roles of the Src Homology 2 Domain-Containing Inositol 5-Phosphatases SHIP1 and SHIP2 in the Pathogenesis of Human Diseases
Müller S, Jücker M
INT J MOL SCI. 2024;25(10):.

Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells
Smit D, Brauer H, Horn S, Yigit G, Haider M, Pogenberg V, Schumacher U, Pantel K, Jücker M
CELL SIGNAL. 2024;121:.

Analysis of the Plasticity of Circulating Tumor Cells Reveals Differentially Regulated Kinases During the Suspension-to-Adherent Transition
Smit D, Hoffer K, Bettin B, Kriegs M, Cayrefourcq L, Schumacher U, Pantel K, Alix-Panabières C, Jücker M
CANCER MED-US. 2024;13(20):e70339.

All Three AKT Isoforms Can Upregulate Oxygen Metabolism and Lactate Production in Human Hepatocellular Carcinoma Cell Lines
Tian L, Smit D, Popova N, Horn S, Velasquez L, Huber S, Jucker M
INT J MOL SCI. 2024;25(4):.

2023

Activated Src kinases downstream of BCR-ABL and Flt3 induces proteasomal degradation of SHIP1 by phosphorylation of tyrosine 1021
Ehm P, Bettin B, Jücker M
BBA-MOL CELL RES. 2023;1870(5):.

Targeted hyperactivation of AKT through inhibition of ectopic expressed SHIP1 induces cell death in colon carcinoma cells and derived metastases
Ehm P, Linnebacher M, Block A, Rehbach C, Jücker M
CELL SIGNAL. 2023;108:110720.

Reduced expression and activity of patient-derived SHIP1 phosphatase domain mutants
Ehm P, Nelson N, Giehler S, Schaks M, Bettin B, Kirchmair J, Jücker M
CELL SIGNAL. 2023;101:.

SHIP1 Is Present but Strongly Downregulated in T-ALL, and after Restoration Suppresses Leukemia Growth in a T-ALL Xenotransplantation Mouse Model
Ehm P, Rietow R, Wegner W, Bußmann L, Kriegs M, Dierck K, Horn S, Streichert T, Horstmann M, Jücker M
CELLS-BASEL. 2023;12(13):1798.

Tumor cell integrin β4 and tumor stroma E-/P-selectin cooperatively regulate tumor growth in vivo
Genduso S, Freytag V, Schetler D, Kirchner L, Schiecke A, Maar H, Wicklein D, Gebauer F, Bröker K, Stürken C, Milde-Langosch K, Oliveira-Ferrer L, Ricklefs F, Ewald F, Wolters-Eisfeld G, Riecken K, Unrau L, Krause L, Bohnenberger H, Offermann A, Perner S, Sebens S, Lamszus K, Diehl L, Linder S, Jücker M, Schumacher U, Lange T
J HEMATOL ONCOL. 2023;16(1):.

Impact of AKT1 on cell invasion and radiosensitivity in a triple negative breast cancer cell line developing brain metastasis
Kempska J, Oliveira-Ferrer L, Grottke A, Qi M, Alawi M, Meyer F, Borgmann K, Hamester F, Eylmann K, Rossberg M, Smit D, Jücker M, Laakmann E, Witzel I, Schmalfeldt B, Müller V, Legler K
FRONT ONCOL. 2023;13:1129682.

Generating Patient-Derived HCC Cell Lines Suitable for Predictive In Vitro and In Vivo Drug Screening by Orthotopic Transplantation
Staffeldt L, Mattert G, Riecken K, Rövenstrunk G, Volkmar A, Heumann A, Moustafa M, Jücker M, Fehse B, Schumacher U, Lüth S, Kah J
CELLS-BASEL. 2023;13(1):.

The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
Tian L, Smit D, Jücker M
INT J MOL SCI. 2023;24(3):.

2022

Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL)
Ehm P, Grottke A, Bettin B, Jücker M
CELL SIGNAL. 2022;93:.

Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer
Elakad O, Häupl B, Labitzky V, Yao S, Küffer S, von Hammerstein-Equord A, Danner B, Jücker M, Urlaub H, Lange T, Ströbel P, Oellerich T, Bohnenberger H
NPJ PRECIS ONCOL. 2022;6(1):.

JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative Neoplasm (MPN)
Glück M, Dally L, Jücker M, Ehm P
INT J BIOCHEM CELL B. 2022;149:.

Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM+ and CD90+ Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model
Moustafa M, Dähling K, Günther A, Riebandt L, Smit D, Riecken K, Schröder C, Zhuang R, Krech T, Kriegs M, Fehse B, Izbicki J, Fischer L, Nashan B, Li J, Jücker M
CANCERS. 2022;14(8):.

The Functional Role of Extracellular Matrix Proteins in Cancer
Popova N, Jücker M
CANCERS. 2022;14(1):.

AKT Isoforms as a Target in Cancer and Immunotherapy
Smit D, Jücker M
2022. PI3K and AKT Isoforms in Immunity. Dominguez-Villar M (Hrsg.). 1. Aufl. Cham: Springer, 409-436.

2021

Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia
Ecker V, Stumpf M, Brandmeier L, Neumayer T, Pfeuffer L, Engleitner T, Ringshausen I, Nelson N, Jücker M, Wanninger S, Zenz T, Wendtner C, Manske K, Steiger K, Rad R, Müschen M, Ruland J, Buchner M
NAT COMMUN. 2021;12(1):3526.

Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGFβ/CTGF Axis
Hinz N, Baranowsky A, Horn M, Kriegs M, Sibbertsen F, Smit D, Clezardin P, Lange T, Schinke T, Jücker M
CELLS-BASEL. 2021;10(2):.

AKT in Bone Metastasis of Solid Tumors: A Comprehensive Review
Hinz N, Jücker M
CANCERS. 2021;13(10):2287.

Truncated O-GalNAc glycans impact on fundamental signaling pathways in pancreatic cancer
Hofmann B, Picksak A, Kwiatkowski M, Grupp K, Jücker M, Bachmann K, Mercanoglu B, Izbicki J, Kahlert C, Bockhorn M, Güngör C, Ewald F, Wolters-Eisfeld G
GLYCOBIOLOGY. 2021;2021:.

AKT1 and PTEN show the highest affinities among phosphoinositide binding proteins for the second messengers PtdIns(3,4,5)P3 and PtdIns(3,4)P2
Nelson N, Razeto A, Gilardi A, Grättinger M, Kirchmair J, Jücker M
BIOCHEM BIOPH RES CO. 2021;568:110-115.

Combined Targeting of AKT and mTOR Synergistically Inhibits Formation of Primary Colorectal Carcinoma Tumouroids In Vitro: A 3D Tumour Model for Pre-therapeutic Drug Screening
Nörz D, Mullins C, Smit D, Linnebacher M, Hagel G, Mirdogan A, Siekiera J, Ehm P, Izbicki J, Block A, Thastrup O, Jücker M
ANTICANCER RES. 2021;41(5):2257-2275.

The Role of mTOR Signaling as a Therapeutic Target in Cancer
Popova N, Jücker M
INT J MOL SCI. 2021;22(4):1743.

Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy
Smit D, Pantel K, Jücker M
BIOCHEM PHARMACOL. 2021;188:114589.

2020

Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity
Koch C, Kuske A, Joosse S, Yigit G, Sflomos G, Thaler S, Smit D, Werner S, Borgmann K, Gärtner S, Mossahebi Mohammadi P, Battista L, Cayrefourcq L, Altmüller J, Salinas-Riester G, Raithatha K, Zibat A, Goy Y, Ott L, Bartkowiak K, Tan T, Zhou Q, Speicher M, Müller V, Gorges T, Jücker M, Thiery J, Brisken C, Riethdorf S, Alix-Panabières C, Pantel K
EMBO MOL MED. 2020;12(9):.

Modeling Spontaneous Bone Metastasis Formation of Solid Human Tumor Xenografts in Mice
Labitzky V, Baranowsky A, Maar H, Hanika S, Starzonek S, Ahlers A, Stübke K, Koziolek E, Heine M, Schäfer P, Windhorst S, Jücker M, Riecken K, Amling M, Schinke T, Schumacher U, Valentiner U, Lange T
CANCERS. 2020;12(2):.

PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer
Marquard F, Jücker M
BIOCHEM PHARMACOL. 2020;172:113729.

Characterization of the substrate specificity of the inositol 5-phosphatase SHIP1
Nelson N, Wundenberg T, Lin H, Rehbach C, Horn S, Windhorst S, Jücker M
BIOCHEM BIOPH RES CO. 2020;524(2):366-370.

Ectopic Expression of Hematopoietic SHIP1 in Human Colorectal Cancer
Schaks M, Allgoewer K, Nelson N, Ehm P, Heumann A, Ewald F, Schumacher U, Simon R, Sauter G, Jücker M
BIOMEDICINES. 2020;8(7):.

Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo
Schulte A, Ewald F, Spyra M, Smit D, Jiang W, Salamon J, Jücker M, Mautner V
INT J MOL SCI. 2020;21(4):.

High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors
Smit D, Cayrefourcq L, Haider M, Hinz N, Pantel K, Alix-Panabières C, Jücker M
CELLS-BASEL. 2020;9(9):.

Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer
Voß H, Wurlitzer M, Smit D, Ewald F, Alawi M, Spohn M, Indenbirken D, Omidi M, David K, Juhl H, Simon R, Sauter G, Fischer L, Izbicki J, Molloy M, Nashan B, Schlüter H, Jücker M
CLIN EXP METASTAS. 2020;37(6):649-656.

2019

Analysis of the FLVR motif of SHIP1 and its importance for the protein stability of SH2 containing signaling proteins
Ehm P, Lange F, Hentschel C, Jepsen A, Glück M, Nelson N, Bettin B, de Bruyn Kops C, Kirchmair J, Nalaskowski M, Jücker M
CELL SIGNAL. 2019;63:109380.

Distinct functions of AKT isoforms in breast cancer: a comprehensive review
Hinz N, Jücker M
CELL COMMUN SIGNAL. 2019;17(1):154.

2018

Nuclear accumulation of SHIP1 mutants derived from AML patients leads to increased proliferation of leukemic cells
Nalaskowski M, Ehm P, Rehbach C, Nelson N, Täger M, Modest K, Jücker M
CELL SIGNAL. 2018;49:87-94.

2017

PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression
Hohensee I, Chuang H, Grottke A, Werner S, Schulte A, Horn S, Lamszus K, Bartkowiak K, Witzel I, Westphal M, Matschke J, Glatzel M, Jücker M, Pukrop T, Pantel K, Wikman H
ONCOTARGET. 2017;8(4):6155-6168.

Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia
Latuske E, Stamm H, Klokow M, Vohwinkel G, Muschhammer J, Bokemeyer C, Jücker M, Kebenko M, Fiedler W, Wellbrock J
ONCOTARGET. 2017;8(17):29187-29201.

SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse model
Täger M, Horn S, Latuske E, Ehm P, Schaks M, Nalaskowski M, Fehse B, Fiedler W, Stocking C, Wellbrock J, Jücker M
GENE THER. 2017;24(11):749-753.

Akt1 and Akt3 but not Akt2 through interaction with DNA-PKcs stimulate proliferation and post-irradiation cell survival of K-RAS-mutated cancer cells
Toulany M, Maier J, Iida M, Rebholz S, Holler M, Grottke A, Jüker M, Wheeler D, Rothbauer U, Rodemann H
CELL DEATH DISCOV. 2017;(3):17072.

Tight Junction Proteins Claudin-1 and Occludin Are Important for Cutaneous Wound Healing
Volksdorf T, Heilmann J, Eming S, Schawjinski K, Zorn-Kruppa M, Ueck C, Vidal-Y-Sy S, Windhorst S, Jücker M, Moll I, Brandner J
AM J PATHOL. 2017;187(6):1301-1312.

2016

Downregulation of AKT3 Increases Migration and Metastasis in Triple Negative Breast Cancer Cells by Upregulating S100A4
Grottke A, Ewald F, Lange T, Nörz D, Herzberger C, Bach J, Grabinski N, Gräser L, Höppner F, Nashan B, Schumacher U, Jücker M
PLOS ONE. 2016;11(1):e0146370.

Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells
Holler M, Grottke A, Mueck K, Manes J, Jücker M, Rodemann H, Toulany M
PLOS ONE. 2016;11(5):e0154745.

Akt isoform specific effects in ovarian cancer progression
Linnerth-Petrik N, Santry L, Moorehead R, Jücker M, Wootton S, Petrik J
ONCOTARGET. 2016;7(46):74820-74833.

2015

The tumor suppressor SHIP1 colocalizes in nucleolar cavities with p53 and components of PML nuclear bodies
Ehm P, Nalaskowski M, Wundenberg T, Jücker M
NUCLEUS-PHILA. 2015;6(2):154-64.

Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma
Ewald F, Nörz D, Grottke A, Bach J, Herzberger C, Hofmann B, Nashan B, Jücker M
J CANCER. 2015;6(12):1195-205.

COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer
Hofmann B, Schlüter L, Lange P, Mercanoglu B, Ewald F, Fölster A, Picksak A, Harder S, El Gammal A, Grupp K, Güngör C, Drenckhan A, Schlüter H, Wagener C, Izbicki J, Jücker M, Bockhorn M, Wolters-Eisfeld G
MOL CANCER. 2015;14(1):109.

ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: Identification of novel targets for concerted therapy concepts
Kebenko M, Drenckhan A, Gros S, Jücker M, Grabinski N, Ewald F, Grottke A, Schultze A, Izbicki J, Bokemeyer C, Wellbrock J, Fiedler W
CELL SIGNAL. 2015;27(2):373-81.

Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion
Nörz D, Grottke A, Bach J, Herzberger C, Hofmann B, Nashan B, Jücker M, Ewald F
CELL SIGNAL. 2015;27(11):2191-200.

Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Wellbrock J, Latuske E, Köhler J, Wagner K, Stamm H, Vettorazzi E, Vohwinkel G, Klokow M, Uibeleisen R, Ehm P, Riecken K, Loges S, Thol F, Schubert C, Amling M, Jücker M, Bokemeyer C, Heuser M, Krauter J, Fiedler W
CLIN CANCER RES. 2015.

Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic acid induced 2
Werner S, Brors B, Eick J, Marques E, Pogenberg V, Parret A, Kemming D, Wood A, Edgren H, Neubauer H, Streichert T, Riethdorf S, Bedi U, Baccelli I, Jücker M, Eils R, Fehm T, Trumpp A, Johnsen S, Klefstrom J, Wilmanns M, Müller V, Pantel K, Wikman-Kocher H
CANCER DISCOV. 2015;5(5):506-19.

2014

"Alkohol und Nikotin"-Konzept und Evaluation eines interdisziplinären Wahlfachs mit OSPE im Studienabschnitt Medizin 1
Bergelt C, Lauke-Wettwer H, Petersen-Ewert C, Jücker M, Bauer C
GMS J MED EDU. 2014;31(1):1-20.

H2S preconditioning of human adipose tissue-derived stem cells increases their efficacy in an in vitro model of cell therapy for simulated ischemia
Dongó E, Benkő Z, Csizmazia Á, Marosi G, Grottke A, Jücker M, Schumacher U, Kiss L
LIFE SCI. 2014;113(1-2):14-21.

Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors
Ewald F, Nörz D, Grottke A, Hofmann B, Nashan B, Jücker M
INVEST NEW DRUG. 2014;32(6):1144-54.

AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice
Grabinski N, Möllmann K, Milde-Langosch K, Müller V, Schumacher U, Brandt B, Pantel K, Jücker M
CELL SIGNAL. 2014;26(5):1021-9.

2013

Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma
Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann B, Diehl F, David K, Schumacher U, Nashan B, Jücker M
INT J CANCER. 2013;133(9):2065-76.

2012

Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling.
Brauer H, Strauss J, Wegner W, Müller-Tidow C, Horstmann M, Jücker M
CELL SIGNAL. 2012;24(11):2095-2101.

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
Grabinski N, Ewald F, Hofmann B, Staufer K, Schumacher U, Nashan B, Jücker M
MOL CANCER. 2012;11:85.

Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
Hofmann B, Jücker M
CELL SIGNAL. 2012;24(10):1950-1954.

The inositol 5-phosphatase SHIP1 is a nucleo-cytoplasmic shuttling protein and enzymatically active in cell nuclei.
Nalaskowski M, Metzner A, Brehm M, Labiadh S, Brauer H, Grabinski N, Mayr G, Jücker M
CELL SIGNAL. 2012;24(3):621-628.

2011

Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells
Grabinski N, Bartkowiak K, Grupp K, Brandt B, Pantel K, Jücker M
CELL SIGNAL. 2011;23(12):1952-1960.

Posttranscriptional regulation of the p85α adapter subunit of phosphatidylinositol 3-kinase in human leukemia cells
Hofmann B, Hoxha E, Mohr E, Schulz K, Jücker M
LEUKEMIA LYMPHOMA. 2011;52(3):467-477.

2009

Reduced proliferation of CD34(+) cells from patients with acute myeloid leukemia after gene transfer of INPP5D.
Metzner A, Precht C, Fehse B, Fiedler W, Stocking C, Günther A, Mayr G, Jücker M
GENE THER. 2009;16(4):570-573.

2008

Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S, Bergholz U, Jücker M, McCubrey J, Trümper L, Stocking C, Bäsecke J
ONCOGENE. 2008;27(29):4096-4106.

2007

Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
Metzner A, Horstmann M, Fehse B, Ortmeyer G, Niemeyer C, Stocking C, Mayr G, Jücker M
GENE THER. 2007;14(8):699-703.

2003

An increase in the expression and total activity of endogenous p60(c-Src) in several factor-independent mutants of a human GM-CSF-dependent leukemia cell line (TF-1)
Horn S, Meyer J, Stocking C, Ostertag W, Jücker M
ONCOGENE. 2003;22(46):7170-80.

2002

Hierarchy of stroma-derived factors in supporting growth of stroma-dependent hemopoietic cells membrane-bound SCF is sufficient to confer stroma competence to epithelial cells
Friel J, Itoh K, Bergholz U, Jücker M, Stocking C, Harrison P, Ostertag W
GROWTH FACTORS. 2002;20(1):35-51.

2001

The inositol 5-phosphatase SHIP is expressed as 145 and 135 kDa proteins in blood and bone marrow cells in vivo, whereas carboxyl-truncated forms of SHIP are generated by proteolytic cleavage in vitro
Horn S, Meyer J, Heukeshoven J, Fehse B, Schulze C, Li S, Frey J, Poll S, Stocking C, Jücker M
LEUKEMIA. 2001;15(1):112-20.

1996

Expression of the neural adhesion molecule L1 in the deafferented dentate gyrus
Jucker M, D'Amato F, Mondadori C, Mohajeri H, Magyar J, Bartsch U, Schachner M
NEUROSCIENCE. 1996;75(3):703-15.

Letzte Aktualisierung aus dem FIS: 20.11.2024 - 23:34 Uhr